Neurocrine Biosciences Inc Q2 2023 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Myles Robert Minter - William Blair & Company L.L.C., Research Division - Analyst : Just on the CTA for 570, the M1/M4 dual agonist here. Are you running that Phase I with any sort of anticholinergic components to mask nausea and vomiting that's been seen with that mechanism, just obviously referring to the xanomeline experience at Eli Lilly. So just curious whether there's an additive compound in that CTA.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Could you remind us as to the nuance that drives the primary endpoint being glucocorticoid reduction at week 24 for adult patients while it's [serum A4] in pediatric patients with glucocorticoid being a secondary endpoint at week 28? And what could this difference mean in terms of your ability to drive successful regulatory discussions in pediatric and adult patients?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Sorry about that. I hope this is better. So could you remind us as to the nuance that drives the primary endpoint being glucocorticoid reduction at week 24 for adult patients while it's [serum A4] in pediatric patients with glucocorticoid being a secondary endpoint at week 28? And what could this difference mean in terms of your ability to drive successful regulatory discussions in pediatric and adult patients?